Related Experiment Videos
Antibody-mediated organ-allograft rejection
Robert B Colvin1, R Neal Smith
1Department of Pathology, Warren 225, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02140, USA. colvin@helix.mgh.harvard.edu
Nature Reviews. Immunology
|September 22, 2005
Summary
Alloantibodies cause significant graft rejection and loss through antibody-mediated mechanisms. Understanding these pathways is crucial for developing new treatments to prevent irreversible graft damage.
Area of Science:
- Immunology
- Transplantation Biology
- Vascular Biology
Background:
- Alloantibodies play a major role in graft rejection episodes, leading to both early and late graft loss.
- Antibody-mediated rejection (AMR) involves distinct mechanisms compared to T-cell mediated rejection, necessitating different therapeutic strategies.
Purpose of the Study:
- To elucidate the mechanisms by which alloantibodies and complement contribute to graft rejection.
- To highlight the distinct pathways of antibody-induced rejection requiring novel treatment and prevention approaches.
Main Methods:
- The study reviews recent findings on alloantibody and complement-mediated graft rejection.
- Mechanisms discussed include complement fixation, coagulation, inflammatory cell recruitment, and endothelial gene expression.
Main Results:
- Antibody-mediated rejection involves complement fixation, leading to tissue injury and coagulation.
- Complement activation recruits inflammatory cells, causing further endothelial damage.
- Antibody and complement induce endothelial gene expression, resulting in irreversible arterial and basement membrane remodeling.
Conclusions:
- Alloantibodies are a significant driver of graft rejection and loss.
- The mechanisms of antibody-mediated rejection differ from T-cell mediated rejection, requiring targeted interventions.
- Understanding these pathways is key to developing effective strategies for preventing long-term graft dysfunction.